Form 4: Health Catalyst Director Spencer Receives RSU Grant

Health Catalyst, Inc. director Justin Spencer was granted 68,572 restricted stock units as part of the company's non-employee director compensation policy.

Summary

• Justin Spencer, a Director of Health Catalyst, Inc. (HCAT), was granted 68,572 restricted stock units (RSUs).
• The grant was made on September 1, 2025, under the company's 2019 Stock Option and Incentive Plan and Non-Employee Director Compensation Policy.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs will vest in three tranches: 33.33% on September 1, 2026, and the remaining 66.67% in two equal annual installments thereafter (September 1, 2027, and September 1, 2028).

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive for aligning interests and retention, but it's a routine event with minimal direct impact on immediate company performance or financial health. It reflects standard corporate governance practices.

Positives

• Aligns the interests of Director Justin Spencer with those of shareholders through equity ownership.
• Serves as a retention mechanism for key board members.
• The grant is part of a pre-existing, disclosed compensation policy, indicating structured governance.

Negatives

• Potential for minor dilution of existing shareholder equity upon vesting and conversion of RSUs into common stock.

Risks

• Future stock price volatility could impact the value of the RSU grant upon vesting.
• The director's continued service is required for vesting, posing a risk of forfeiture if service ceases prematurely.

Future Outlook

The RSU grant outlines a future vesting schedule extending through September 1, 2028, contingent on Director Spencer's continued service, indicating a long-term incentive structure.

Industry Context

Equity grants, particularly Restricted Stock Units (RSUs), are a standard component of non-employee director compensation across many industries, including healthcare technology. This practice aims to align director incentives with long-term shareholder value creation and ensure board member retention.

Comparison to Industry Standards

• The use of RSUs for non-employee director compensation is a common practice, aligning with governance best practices seen in companies like Veeva Systems (VEEV) or Cerner (now Oracle Health), which also utilize equity-based incentives for their board members.
• The multi-year vesting schedule is typical for such grants, promoting long-term commitment, similar to director compensation structures at peer companies in the health tech sector.
• The grant size of 68,572 RSUs is within the expected range for a director at a company of Health Catalyst's market capitalization, comparable to grants observed at similar-sized public companies in the software and healthcare IT space.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor potential for dilution upon vesting, but improved alignment of director interests with long-term shareholder value.

Next Steps

• Vesting of 33.33% of RSUs on September 1, 2026.
• Vesting of remaining RSUs in two equal annual installments on September 1, 2027, and September 1, 2028.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a non-employee director, which is a standard compensation practice aimed at aligning interests and retaining talent. It does not contain information that would significantly alter the fundamental investment thesis for Health Catalyst, Inc. Therefore, a 'hold' recommendation is appropriate as this event is neutral to the company's immediate financial prospects or strategic direction.

Keywords

Health Catalyst, HCAT, Justin Spencer, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Form 4, Insider Transaction, Stock Option Plan